Navidea Biopharmaceuticals, Inc.
NAVB · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.15 | 0.13 | 0.03 |
| FCF Yield | -152.17% | -35.95% | -16.72% | -51.89% |
| EV / EBITDA | -0.47 | -2.25 | -4.70 | -1.68 |
| Quality | ||||
| ROIC | 280.59% | -582.25% | -262.32% | -963.02% |
| Gross Margin | -259.40% | 62.59% | 99.89% | 74.95% |
| Cash Conversion Ratio | 0.59 | 0.87 | 0.76 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -58.45% | 171.30% | 41.57% | -75.50% |
| Free Cash Flow Growth | 11.10% | -22.82% | 8.75% | -322.53% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | 0.30 | 0.13 | -0.00 |
| Interest Coverage | -12.79 | -1,895.99 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.43 | 1.32 | 0.01 | -0.01 |
| Cash Conversion Cycle | -3,342.03 | -2,267.78 | -344,276.33 | -97,868.94 |